Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver Lee P, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM; ATBAT Investigators. Mahaffey KW, et al. Among authors: turco ma. J Invasive Cardiol. 2003 Nov;15(11):611-6. J Invasive Cardiol. 2003. PMID: 14608128
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, Mehran R, Stone GW; CADILLAC Investigators. Kandzari DE, et al. Am J Cardiol. 2003 Oct 1;92(7):779-84. doi: 10.1016/s0002-9149(03)00882-8. Am J Cardiol. 2003. PMID: 14516875 Clinical Trial.
Defining the length of stay following percutaneous coronary intervention: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Endorsed by the American College of Cardiology Foundation.
Chambers CE, Dehmer GJ, Cox DA, Harrington RA, Babb JD, Popma JJ, Turco MA, Weiner BH, Tommaso CL; Society for Cardiovascular Angiography and Interventions. Chambers CE, et al. Among authors: turco ma. Catheter Cardiovasc Interv. 2009 Jun 1;73(7):847-58. doi: 10.1002/ccd.22100. Catheter Cardiovasc Interv. 2009. PMID: 19425053 Review.
Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O'Neill WW, Lansky AJ, Griffin JJ; CADILLAC Investigators. Cox DA, et al. Am J Cardiol. 2006 Aug 1;98(3):331-7. doi: 10.1016/j.amjcard.2006.01.102. Epub 2006 Jun 9. Am J Cardiol. 2006. PMID: 16860018 Clinical Trial.
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE; ENDEAVOR III Investigators. Kandzari DE, et al. J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7. doi: 10.1016/j.jacc.2006.08.035. Epub 2006 Nov 28. J Am Coll Cardiol. 2006. PMID: 17174180 Free article. Clinical Trial.
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.
Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, Stone GW; CADILLAC Investigators. Kandzari DE, et al. Am Heart J. 2006 Jun;151(6):1288-95. doi: 10.1016/j.ahj.2005.08.017. Am Heart J. 2006. PMID: 16781238
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. Krucoff MW, et al. Among authors: turco ma. J Am Coll Cardiol. 2008 Apr 22;51(16):1543-52. doi: 10.1016/j.jacc.2008.01.020. J Am Coll Cardiol. 2008. PMID: 18420096 Free article. Clinical Trial.
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators. Tcheng JE, et al. Circulation. 2003 Sep 16;108(11):1316-23. doi: 10.1161/01.CIR.0000087601.45803.86. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939213 Clinical Trial.
Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Na Y, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Rutherford BD, Lansky AJ, Mehran R. Harjai KJ, et al. Am J Cardiol. 2007 Jan 15;99(2):202-7. doi: 10.1016/j.amjcard.2006.07.084. Epub 2006 Nov 16. Am J Cardiol. 2007. PMID: 17223419 Clinical Trial.
89 results